Abstract-Rotaviruses cause an infectious disease that is the main cause of severe diarrhea in children all over the world and one of the factors that determine the level of child mortality. Only live attenuated vaccines are currently used against rotavirus infection. These vaccines are efficient, but a range of side effects, including intussusception risk, is characteristic of them. Complications associated with the use of existing vaccines usually occur in the case of oral administration and develop as the attenuated live vaccines start to replicate in the human intestine. Thus, there is a need for development of modern, efficient, and safe preparations for the prevention of rotavirus infection. These preparations should be incapable of reproduction (replication) in the organism after vaccination. Recombinant vaccines represent a new generation of vaccines against rotavirus infection, and the development and testing of such vaccines, including those intended for parenteral administration, has progressed considerably during recent years. The complex antigenic structure of the rotavirus is one of the problems associated with the production of these vaccines. The present review summarizes published data on genetic and antigenic diversity of rotavirus strains and geographic localization of epidemiologically significant virus variants. The role of capsid proteins in the emergence of immune response against the virus and the current state of research on new candidate recombinant vaccines against rotavirus infection are discussed.
Acute enteric infections are currently among the most frequent infectious diseases in children younger than 5 years of age. Group A rotaviruses (RVs) are the most common causative agents of severe gastroenteritis in young children all over the world, since 2 million hospital admissions and 24 million hospital visits are registered annually. Approximately 215 000 children younger than 5 years of age die of rotavirus gastroenteritis, with up to 56% lethal outcomes registered in Africa and 22% in India [1] [2] [3] . However, epidemiological studies show that the problem is also rather challenging for economically developed countries [4] . The monovalent Rotarix vaccine and the pentavalent RotaTeq vaccine currently used for rotavirus infection (RVI) prevention are based on live attenuated human and/or animal virus strains capable of replication in the human intestine. The introduction of rotavirus vaccines into use considerably reduced the number of hospital admissions for RVI [5] , but vaccination can evoke side effects, primarily intussusception. Additional risks are related to the documented cases of reassortant virus formation from vaccine strains and circulating wild-type viruses. Moreover, there is a risk of vaccine strain reversion into a virulent state. The cost of attenuated vaccines and the rigid requirements for vaccine transportation and storage are the reasons for the relatively low efficiency of their use in economically undeveloped countries (as compared to countries with a high living standard). The drawbacks of attenuated vaccines stimulate the development of recombinant vaccines against RVI that could provide efficient and safe solutions at a lower cost. Grave consequences of attenuated vaccine use, such as intussusception, are presumably related to oral vaccine replication in the intestine and can be prevented if parenteral administration of nonreplicating vaccines (incapable of reproduction in the patient's organism) is used. Parenteral vaccines are successfully used for the treatment of diseases caused by mucosal pathogens, such as poliovirus, hepatitis A virus, and Vibrio cholerae. Vaccination by parenteral administration of inactivated rotavirus particles is under consideration as an alternative for the vaccines commonly used at present [6] . New-generation candidate vaccines against RVI, mostly represented by recombinant vaccines, including those for parenteral administration, are at different stages of development and preclinical and clinical trials.
The present review summarizes published data on genetic and antigenic diversity of RV strains and geographic localization of virus variants of epidemical risk. The role of capsid proteins in the emergence of immune response against the virus and the current VIROLOGY state of research on new candidate recombinant vaccines against RVI are discussed.
ROTAVIRUS VIRION STRUCTURE
RVs belong to the Reoviridae family of the genus Rotavirus. The RV genome consists of 11 doublestranded RNA segments that encode six structural proteins (VP1-VP4, VP6, and VP7) and five or six nonstructural proteins (NSP1-NSP6) in different strains [7, 8] . A mature infectious RV particle (virion) has a nearly spherical form (approximately 100 nm in diameter) and consists of three concentric protein layers (triple-layered particle, TLP). The internal layer, also termed the core, of approximately 40 nm in diameter is icosahedral (Т = 1) and composed of 60 asymmetric dimers of VP2 protein that envelop the virus genome and two minor proteins VP1 and VP3 (transcription enzymes). VP1 and VP3 are anchored to the internal envelope of the virus formed by the VP2 protein in an area adjacent to 12 channels that run along the fifth-order symmetry axes. The virion core is surrounded by 260 VP6 protein trimers that form the middle layer (Т = 13) and constitute the noninfectious transcriptionally active double-layered particles (DLPs) of approximately 80 nm in diameter. Efficient initiation of RVI occurs as DLPs get into the cytoplasm and virus transcript synthesis begins. The outer layer is an icosahedral capsid, similarly to the middle layer. This layer consists of 260 VP7 glycoprotein trimers (Т = 13) and contains 60 spikes formed by asymmetric VP4 protein trimers VP4 [9] [10] [11] [12] [13] [14] . VP4 and VP7 proteins are the main targets of virus-neutralizing antibodies. VP4 is cleaved into VP5* and VP8* domains by trypsin-like proteases, and the infectious capacity of the virus increases considerably after this event. The presence of 132 channels of three types that penetrate the outer and middle layers is among the distinctive features of RV virions. These channels are subdivided into 12 type I channels that run along fifthorder symmetry axes, 60 type II channels that surround type I channels, and 60 type III channels that surround third-order symmetry axes. Type I channels penetrate the VP2 protein layer and serve as exit pathways for viral mRNA during transcription [7] .
ROTAVIRUS CLASSIFICATION AND STRAIN DIVERSITY
RV classification is based on antigenic differences in VP6 proteins that allow for the subdivision of virus strains into at least eight groups (А-H) [15] . The representatives of А, B, С, and H groups can infect humans and animals, whereas those of the groups D, E, F, and G were only found in birds or swine. Two strains recently isolated from dogs and bats were preliminarily assigned to two new groups (RV I and J) [15] [16] [17] [18] [19] . RV strains of the group A are the major causative agents of human disease all over the world [20, 21] . These strains, in turn, were subdivided into four serological subgroups referred to as SG I, II, I+II, and non I/II according to the presence or absence of VP6-specific epitopes. Strains that infect humans usually belong to SG I or SG II subgroups and show a high level of conservation (87-95%) of the VP6 amino acid sequence [22] .
A binary classification of RV strains is based on the sequences of the two major viral antigens VP7 (G-protein) and VP4 (P-protein), structural proteins of the external capsid that are targeted by virus-neutralizing antibodies. This classification characterizes the combinations of G and Р RV serotypes [23] . The serotype classification system has been almost fully replaced by the G and Р genotype classification system by now; the genotype classification is based on differences in the sequences of RNA segments that code for these proteins. Rather good agreement between G (protein VP7) serotypes and G genotypes was demonstrated and, therefore, the identifier system was unified. Classification of VP4 protein serotype and genotype follows a double nomenclature, with the P serotype (when known, for instance, P1A) being put into correspondence with the P genotype shown in square brackets (for instance, P [8] ). P serotype is shown before P genotype if both are known (for instance, P1A [8] ). Twenty-seven G genotypes and 37 P genotypes (referred to as G and P types below for briefness) of human and animal RV А are currently known [24, 25] . High diversity of the strains is related to the segmented nature of the genome and reassortment capacity. Twelve G-types, 15 P-types, and more than 70 G-P type combinations were reported in RV A from humans by 2012 (Table 1) [19, 26] . Fourteen G types, 17 P types, and nearly 90 G-P combinations were known in 2015 [27] . The emergence of new G-P type combinations, including those capable of local outbreak induction in vaccinated populations, was observed.
RV strains that can infect humans are found all over the world, although there are certain differences between regions and seasonal oscillations of infection manifestations during the year. Meta-analysis showed that four G-types (G1, G2, G3, and G4) combined with P [8] or P [4] accounted for 88% of all virus strains that caused RVI in the years 1989-2004. Strains of the G1P [8] type accounted for more than 70% of RVI cases in North America, Europe, and Australia but only for 30% of infections in South America and Asia and 23% in Africa. Moreover, onethird of all strains identified in Africa belonged to the P [6] type [28] . Meta-analysis performed in 2007-2012 showed that G1P [8] , G2P [4] , G3P [8] , G4P [8] , G9 [8] , and G12P [8] were the most common G and Р type combinations and accounted for 73% of all circulating strains, with G1P [8] predominating [27] .
An RV classification system based on nucleotide analysis of all 11 RNA segments was proposed in 2008.
This classification system enables a better understanding of genomic and antigenic diversity of RV strains. The system assigns a specific genotype to each of 11 RNA segments, and the VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-NSP4-NSP5/6 of different RV А strains are described using the Gx-P[x]-Ix-RxCx-Mx-Ax-Nx-Tx-Ex-Hx abbreviation. This classification assigns the overwhelming majority of all human RV А strains to one of the two typical genotype constallations (different from G and P) termed Wa-like (I1-R1-C1-M1-A1-N1-T1-E1-H1) and DS-1-like (I2-R2-С2-М2-А2-Н2-Т2-E2-H2) [29] .
ROLE OF ROTAVIRUS CAPSID PROTEINS VP7, VP4, AND VP6 IN IMMUNE RESPONSE FORMATION
Numerous studies demonstrated the importance of the humoral component of immunity in protection from RVI. Chiba et al. [30] were the first to show that RV protection was related to the levels of neutralizing antibodies against a homologous virus serotype. Neutralizing antibody level of 1/128 or higher conferred protection from the disease. Subsequent studies reported the existence of both homotypic antibodies that targeted viruses of the same type that caused the infection and heterotypic antibodies that could neutralize other variants (with different G-P-types), which was indicative of the presence of cross-reactive virus-neutralizing epitopes [31, 32] .
A number of studies identified VP4 and VP7 proteins of the outer capsid layer as the major targets of virus-neutralizing antibodies. Trypsin cleaves the VP4 protein into two domains: VP8* and VP5*. VP8* forms the head of the virion spike and interacts with cell receptors. For instance, a recent study showed that VP8* was capable of specific interactions with histoblood group antigens (HBGA) expressed on epithelial cells of intestinal mucosa [33] [34] [35] . Antibodies against the VP8* domain were assumed (by analogy to norovirus) to block RV interaction with HBGA and, thus, to confer protection by blocking virion adsorption. Productive infection caused by many RV А types, including human strains, in permissive cells also depends on virion binding to receptors of the integrin family. Monoclonal neutralizing antibodies were shown to inhibit VP5* domain binding to integrin α2β1 and VP7 protein binding to integrin α4β1 [36] . Virus-neutralizing epitopes of VP5*, VP8*, and VP7 proteins were identified [37] [38] [39] [40] [41] . Regardless of the obvious contribution of specific antibodies against VP4 and VP7 to efficient protection against the virus, VP6 protein is also supposed to be an important factor in immune response [42] . Large amounts of VP6-specific antibodies are produced after infection and vaccination [43] , and these antibodies are the main product of В-cells in response to RVI [44] [45] [46] . VP6-specific antibodies were recently shown to neutralize the virus intracellularly according to an unusual mechanism, regardless of the absence of neutralizing epitopes. Antibodies against VP6 were shown to inhibit intracellular virus transcription by binding to type I channels and, thus, blocking mRNA exit from DLPs [47] .
The role of Т-cell immune response in protection against RV is poorly characterized, but chronic RVI in children with T-and/or B-cell immunodeficiency points at the important role of both humoral and cellular components of immunity [48] . VP6-specific CD4(+) T-helpers were shown to contribute substantially to the induction of the protective immune response [49, 50] . CD4(+)-Т-cell epitopes of the VP6 protein were identified in a number of studies [51, 52] . +  -+  ++  -++  -+++  +  +  +  +  +  --G2  ---+++  -++  -++  +  +  +  ----G3  --+  ++  -++  -+++  +  +  +  +  +  --G4  +  --++  -++  -+++  +  +  +  +  ---G5  +  ----+  +  +  -------G6 --- 
LIVE ATTENUATED VACCINES
Two live attenuated vaccines, the monovalent Rotarix vaccine (GlaxoSmithKline, Belgium) (RV1) and the pentavalent RotaTeq vaccine (Merck & Co., United States) (RV5) are currently in wide use for the immunization of children in more than 100 countries. Moreover, three live attenuated monovalent vaccines that received national licenses are used in India, China, and Vietnam, and some candidate vaccines, both monovalent and multivalent, are at different clinical trial stages [53] .
The Rotarix vaccine is derived from an attenuated human strain RIX4414 with a G1P1A [8] genotype. The RotaTeq vaccine includes five monoreassortant strains derived from the bovine SW3 strain (G6P7 [5] ); these strains represent human genotypes G1, G2, G3, G4, and P1A [8] . Analysis of research data obtained in 24 countries and reflected in scientific publications (48 articles) between 2006 and 2016 demonstrated approximately similar efficiency of RV1 and RV5 vaccines in rotavirus diarrhea prevention: the median values for RV1 were 84%, 75%, and 57% in countries with low, moderate, and high child mortality levels, respectively, and those for RV5 were 90% in countries with low child mortality and 45% in countries with high child mortality [54] . Large-scale clinical trials performed prior to vaccine licensing confirmed the safety of RV1 and RV5, but reports on severe side effects, primarily intussusception, have been accumulating lately. A study recently performed in the United States revealed a considerable increase of intussusception frequency among infants vaccinated by RV1 (from 0.72 to 5.3 cases per 100 000 vaccinated children) [55] . Similar data for RV5 were obtained in Australia and the United States [56, 57] . Meta-analysis performed in 2017 showed that intussusception risk depended on age at the time of vaccination and was approximately 1 in 50 000 vaccinated children if the vaccination was performed before the age of 12 weeks and 1 in 20 000 vaccinated children if the first vaccination was performed at a later age [58] . These data cause serious concerns, since the first reassortant vaccine variant licensed in the United States was withdrawn in 1999, one year after the beginning of use, due to intussusception frequency increase to 10 cases per 100 000 vaccinations [59] . Additional risks are related to documented cases of new reassortant formation from vaccine strains and circulating wild-type viruses [60] [61] [62] [63] . There is also a potential risk of vaccine strain reversion into a virulent state. Moreover, contamination of RV1 and RV5 vaccine preparations by swine circovirus DNA (of types PCV1 and PCV2, respectively) was reported [64] .
However, the main problem associated with the use of RV1 and RV5 consists in the decrease of oral vaccine efficiency in countries with low living standards. This decrease is supposedly due to high levels of specific maternal anti-RV antibodies acquired via the placental pathway or breast milk, intestinal coinfections, serotype differences between the vaccine and the circulating RV strains, and vitamin and zinc deficiency [65, 66] . Moreover, increasing migration activity all over the world presents a risk of vaccination efficiency decrease in the case of emergence and spreading of new RV strains of epidemiological significance [67] .
RECOMBINANT VACCINES Vaccines based on recombinant viral and bacterial vectors were recently proposed as a new approach for RVI prevention. Xie et al. [68] demonstrated efficient stimulation of immune response and considerable protection from infection in newborn mice immunized intramuscularly and intranasally with a recombinant adenovirus that carried RV VP4 and NSP4 genes. Girard et al. [69] generated another recombinant adenovirus vector that contained VP4 and VP7 protein genes and a gene for the bacterial protein flagellin that served as an adjuvant. Antigen specificity and immunogenicity of the recombinant vaccine were evaluated in mice, and the vaccine was shown to have potential for clinical applications. Several research groups are working on bacterial vector-based vaccines against RVI that include a nonpathogenic Lactococcus lactis strain. Efficient stimulation of immune response to VP7 [70] , VP8 [71] , VP4 [72] , and VP6 [73] RV proteins obtained from RV strains of different animal species was demonstrated after oral administration of the abovementioned proteins to mice in a L. lactis-based recombinant vector. However, these approaches are still at a stage of development and early preclinical studies.
The development of experimental DNA vaccines encoding VP4, VP6, or VP7 proteins [74] [75] [76] [77] [78] [79] [80] [81] has been in progress since 1996, but the authors are not aware of studies on the development of DNA vaccines against RVI published within the last 10 years.
Another promising approach involves the production of RV virus-like particles (VLPs). VLPs are produced from structural virus proteins, and the spatial structure and antigenic properties of the particles are similar to those of the native virus. VLPs are devoid of virus genetic material and are, therefore, safe. Numerous studies showed that simultaneous expression of structural RV proteins in the cell resulted in VLP formation by self-assembly. VLP RV production in plants [82] and mammalian cells [83] was attempted, but the use of baculovirus expression system in insect cells has been most successful [84] [85] [86] [87] [88] [89] . VP2 forms empty particles in the absence of other proteins. Simultaneous coexpression of VP2 and VP6 proteins leads to in vivo formation of bilayer VLPs (2/6-VLP) similar to DLPs, whereas coexpression of VP2, VP6, and VP7 with or without VP4 leads to the formation of three-layer VLPs (2/6/7-VLP or 2/4/6/7-VLP) similar to infectious TLPs. Preclinical studies in various animal models demonstrated the immunogenicity of these VLPs and various degrees of protection from subsequent infection with the virus. Protection efficiency depended on protein composition in the VLP, administration route, adjuvant type, and animal species. For instance, 2/6-VLPs were immunogenic and conferred partial protection in mice but not in newborn gnotobiotic pigs [89] [90] [91] [92] . Production of 2/4/6/7-VLPs that contain the VP8 protein is associated with certain difficulties and restrictions, such as low particle yield. Therefore, attempts are made to use capsid proteins of other viruses to create various bioengineered VLPs with RV antigenic determinants on the surface. A candidate vaccine that contained 24 copies of VP8* fragment (amino acid residues 64-223) was obtained with norovirus P particles as the carrier [93] . Tests in animals (mice) showed that the titers of VP8*-specific and neutralizing antibodies were higher than those evoked by free VP8*, and the RVI protection levels were considerably higher. The same approach was used to design recombinant vaccines based on a VP8* protein complex with carrier proteins of virus origin [94] . Coexpression of the recombinant VP8* protein and a carrier protein (a structural protein of murine polyomavirus) in E. coli and subsequent VLP assembly in vitro have been reported. This approach allowed for a higher VLP yield and candidate vaccine cost reduction [95] . Notwithstanding the large number of studies and reports, the design of VLP vaccines against RVI is still on the preclinical stage.
The McNeal group developed a recombinant vaccine that contained VP6 protein fused to maltosebinding protein (MBP-VP6). The protection from two murine RV strains in mice immunized with MBP-VP6 amounted to 100%, but the presence of an additional adjuvant was necessary for this result [96, 97] .
The study by Dukhovlinov et al. [98] demonstrated the efficiency of a recombinant vaccine based on a hybrid FliCVP6VP8 protein (a fusion of a VP6 and VP8 protein fragments with Salmonella typhimurium FliC flagellin components as the adjuvant) for RVI prevention in mice. Two instances of intramuscular injection of the candidate vaccine conferred efficient protection. Complete protection from a murine RV strain after oral administration of the virus to the animals immunized by the candidate vaccine was due to virus-specific IgA and IgG production in the intestine and blood serum of the animals. The authors stated that the candidate anti-RVI vaccine based on the recombinant FliCVP6VP8 protein matched the commercial RV1 vaccine in efficiency and surpassed it in safety.
A vaccine obtained by expressing the VP8* protein from the human Wa virus strain (G1P1A [8] ) in E. coli was the most successful of candidate recombinant vaccines. Parenteral administration of the recombinant VP8 protein to animals was shown to induce high titers of homotypic neutralizing antibodies and varying [99, 100] . Virus-neutralizing antibodies against a homologous Wa strain and 89-12 strain (G1P [8] ) were identified in more than 80% of infants. Virus-neutralizing heterotypic antibodies against the Ds-1 strain (G2P [4] ) and the 1076 strain (G2P [6] ) were identified in 32-50% and 17-23% children, respectively [100] . Vaccination by P2-VP8-P [8] did not have a negative effect on the subsequent immune response to RV1, this being highly relevant for combined use of parenteral and oral vaccines in order to attain maximal protection. Information on recombinant vaccines being developed is summarized in Table 2 .
Live attenuated vaccines against RVI are rather efficient in countries with high standards of living. However, the risks associated with the use of these vaccines and low efficiency of vaccination in economically underdeveloped countries characterized by high child mortality point at the necessity of developing new approaches for the generation of vaccines against RVs. Recombinant vaccines, including those developed for parenteral administration, provide an alternative strategy for RVI prevention. The development of an efficient and safe recombinant vaccine is a rather complicated task due to a number of reasons, primarily to antigenic determinant diversity and variability within a genotype and to scarce and controversial data on the mechanisms that confer protection against a wide range of RV genotypes and strains. Structural RV proteins VP4, VP6, and VP7 contain the major epitopes that can induce a strong protective immune response and, therefore, serve as the basic components of modern vaccines. Subunit recombinant vaccines, including those obtained in systems with carrier proteins, and vaccines based on virus-like particles have considerable potential. These nonreplicating vaccines will be safe, and the vaccine production process is expected to be more rapid and cost-effective than the production of new attenuated vaccines. This would allow for a timely response to changes in the epidemiological situation and take the geographical changes in RV genotype distribution into account.
ACKNOWLEDGMENTS
The present study was supported by the Russian Science Foundation (project no. 14-24-00007).
MOSCOW UNIVERSITY BIOLOGICAL SCIENCES BULLETIN
Vol. 72 No. 4 2017
